Infinium Pharmachem
Infinium Pharmachem (INFINIUM) share price was ₹275.05 at the 28 Oct 2026 close; market capitalisation ₹429 Cr; sector Healthcare. The share price rose 10.2% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Mar 2026 quarter, revenue was ₹106 Cr, against ₹73 Cr a year earlier and net profit was ₹8 Cr, against ₹3 Cr a year earlier (compared with Mar 2025). Promoters held 64.91% of Infinium Pharmachem in Mar 2026, up 5.00 percentage points from Sep 2025. Its Tapetide Score is 65/100 (Good) as of 28 Oct 2026.
Key Fundamentals
SMEPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of 29 Oct 2026, 10:54 IST · TTM
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,765.10 | 35.01 | 4,23,507 Cr | 5.07 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,651.00 | 87.59 | 2,56,204 Cr | 15.29 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,595.60 | 72.14 | 1,74,802 Cr | 9.51 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,190.00 | 108.20 | 1,18,328 Cr | 22.33 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,181.40 | 26.29 | 1,17,845 Cr | 4.35 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,337.70 | 34.65 | 1,11,655 Cr | 2.88 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,362.00 | 32.63 | 1,10,030 Cr | 3.11 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
| Infinium Pharmachem (this company) | ₹281.00 | — | 438 Cr | 3.62 | 0.00% | 10.26% | 14.11% | — | — |
| Median 8 companies | ₹1,563.55 | 35.01 | 1,18,087 Cr | 4.71 | 0.47% | 12.98% | 16.41% | 28,515 Cr | 3,184 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Data confidence 84/100
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Company has reduced debt.
Weaknesses
3- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 14.0% over last 3 years.
- Promoter holding has decreased over last 3 years: -8.14%
Technical Indicators
Oscillators
Bullish
Overall
Bearish
Moving Averages
Bearish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 11% · Mar 2026
Quarterly Results
| Particulars | Sep 2022 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 79 | 61 | 74 | 83 | 73 | 84 | 106 |
| Expenses | 71 | 51 | 66 | 75 | 65 | 74 | 94 |
| Operating Profit | 9 | 10 | 8 | 8 | 8 | 10 | 11 |
| OPM % | 11% | 17% | 11% | 10% | 11% | 12% | 11% |
| Other Income | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Interest | 1 | 1 | 1 | 2 | 2 | 2 | 1 |
| Depreciation | 0 | 1 | 1 | 2 | 2 | 2 | 2 |
| PBT | 8 | 8 | 7 | 6 | 5 | 8 | 10 |
| Tax % | 22% | 24% | 24% | 25% | 41% | 22% | 19% |
| Net Profit | 6 | 6 | 5 | 5 | 3 | 7 | 8 |
| EPS (₹) | 5.4 | 4.46 | 3.66 | 3.17 | 2.4 | 3.59 | 4.2 |
Profit & Loss
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 39 | 71 | 99 | 114 | 136 | 156 | 190 |
| Expenses | 36 | 66 | 89 | 98 | 117 | 136 | 168 |
| Operating Profit | 2 | 5 | 10 | 16 | 19 | 19 | 22 |
| OPM % | 6% | 7% | 10% | 14% | 14% | 12% | 11% |
| Other Income | 1 | 1 | 1 | 1 | 2 | -1 | 2 |
| Interest | 1 | 1 | 2 | 3 | 2 | 4 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 3 | 3 | 3 |
| PBT | 1 | 4 | 9 | 13 | 15 | 12 | 18 |
| Tax % | 30% | 28% | 23% | 24% | 24% | 32% | 20% |
| Net Profit | 1 | 3 | 7 | 10 | 12 | 8 | 14 |
| EPS (₹) | 0.93 | 2.72 | 6.11 | 9.3 | 8.12 | 5.23 | 7.8 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 5 | 14 | 16 | 16 |
| Reserves | 3 | 6 | 12 | 17 | 45 | 94 | 105 |
| Borrowings | 9 | 11 | 23 | 29 | 11 | 52 | 23 |
| Other Liabilities | 9 | 17 | 23 | 19 | 15 | 37 | 31 |
| Total Liabilities | 22 | 34 | 59 | 71 | 85 | 198 | 175 |
| Fixed Assets | 4 | 5 | 4 | 19 | 20 | 24 | 23 |
| CWIP | 0 | 4 | 8 | 0 | 0 | 1 | 8 |
| Investments | 0 | 0 | 0 | 0 | 0 | 29 | 29 |
| Other Assets | 18 | 26 | 46 | 52 | 66 | 144 | 114 |
| Total Assets | 22 | 34 | 59 | 71 | 85 | 198 | 175 |
Cash Flow
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | 3 | 7 | 12 | 9 | -13 | -29 | 34 |
| Investing | -1 | -5 | -7 | -5 | -4 | -27 | -7 |
| Financing | -1 | -1 | -2 | -3 | 23 | 79 | -32 |
| Net Cash Flow | 1 | 1 | 3 | 1 | 6 | 23 | -5 |
| Free Cash Flow | 2 | 2 | 7 | 1 | -17 | -38 | 24 |
| CFO/EBITDA | 137 | 168 | 137 | 73 | -51 | -131 | 173 |
Ratios
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 75 | 59 | 57 | 49 | 55 | 79 | 61 |
| Inventory Days | 84 | 62 | 78 | 89 | 87 | 137 | 96 |
| Days Payable | 82 | 79 | 56 | 31 | 16 | 38 | 10 |
| Cash Conversion Cycle | 76 | 43 | 78 | 108 | 126 | 178 | 146 |
| Working Capital Days | 46 | 12 | 25 | 27 | 96 | 97 | 99 |
| ROCE % | — | 32% | 38% | 36% | 28% | 15% | 12% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Infinium Pharmachem insights
65 extracted metrics + investor summaries across FY20–FY26.
Documents
Frequently Asked Questions about Infinium Pharmachem
What does Infinium Pharmachem Ltd do?
Where is Infinium Pharmachem Ltd (INFINIUM) listed?
Which sector does Infinium Pharmachem Ltd belong to?
What is the market capitalisation of Infinium Pharmachem Ltd?
What is the 52-week high and low of Infinium Pharmachem Ltd?
What is the Return on Equity (ROE) of Infinium Pharmachem Ltd?
Company Information
Incorporated in 2003, Infinium Pharmachem Ltd manufactures and sells Iodian based Pharmaceutical Intermediates[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/INFINIUM.md for Infinium Pharmachem Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.